Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study.

Caffo O, Fratino L, Barbieri R, Perin A, Martini T, Sava T, Segati R, Vaccher E, Bernardo Bassan F, Veccia A, Pappagallo G, Galligioni E. Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study. Urol Oncol. 2013 Feb; 31(2):180-6.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.